Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy

• Status: Completed
• Trial end date: 2016-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The pathogenesis of dilated cardiomyopathy (DCM) leading to heart failure is closely associated with autoimmunity dysfunction. A few studies represented that Qiliqiangxin capsule, a Chinese medicine, could enhance heart function in chronic heart failure and regulate the balance of TNF-a and IL-10 in myocardial infarction. In this study, to explore the effects of Qiliqiangxin capsule on the improving heart function and immunoregulation in patients with DCM, patients were recruited, anti-heart autoantibodies and some representative cytokines were assayed by enzyme-linked immuno sorbent assay (ELISA), and the efficacy of heart function improvement was compared between Qiliqiangxin capsule and placebo under the standard treatment of DCM.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huazhong University of Science and Technology
• Collaborators: China National Center for Cardiovascular Diseases; China Three Gorges University, Yichang, China; First Affiliated Hospital of Guangxi Medical University; First Affiliated Hospital of Harbin Medical University; First Affiliated Hospital Xi'an Jiaotong University; Fudan University; Guangxi Medical University; Harbin Medical University; Health Science Center of Xi’an Jiaotong University; Henan Provincial People's Hospital; Jingzhou Central Hospital; Jining Medical University; Ministry of Science and Technology of the People´s Republic of China; RenJi Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Second Hospital of Shanxi Medical University; Shandong Provincial Hospital; Shanxi cardiovascular hospital; Shanxi Medical University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital with Nanjing Medical University; The Second Affiliated Hospital of Harbin Medical University; Tianyou hospital affiliated to Wuhan University of Science and Technology; Tongji Hospital; Wuhan No.1 Hospital; Wuhan Pu-Ai Hospital; Wuhan Union Hospital, China; Wuhan University; Xiangyang Central Hospital; Yunyang Medical College

Criteria

Inclusion Criteria:

• Dilated Cardiomyopathy (LVEF ≤ 45%)

Exclusion Criteria:

• Secondary dilated cardiomyopathy (such as ischemic cardiomyopathy, valvular cardiomyopathy, hyperthyroid cardiomyopathy, diabetic cardiomyopathy, anemia cardiomyopathy, and etc.)

• Coronary heart disease

• Rheumatic heart disease

• Pulmonary heart disease

• Continuous dysarteriotony: hypertension(systolic blood pressure [SBP] ≥ 60mmHg/diastolic blood pressure [DBP] ≥ 100mmHg); hypotension(SBP < 90mmHg/DBP < 60mmHg)

• Resting heart rate ≤ 50bpm

• Atrioventricular block patients without permanent pacemaker